argenx SE is a commercial-stage biopharmaceutical company that specializes in the discovery, development, and commercialization of novel antibody-based medicines for severe autoimmune diseases. The company's proprietary discovery platform, Simple Antibody, leverages the unique characteristics of the llama immune system to create highly differentiated therapeutic candidates. argenx's lead commercial product is VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) blocker that reduces circulating disease-causing immunoglobulin G (IgG) autoantibodies. VYVGART is approved in multiple regions, including the United States, Europe, Japan, and China, for the treatment of generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), and is available in both intravenous and subcutaneous formulations (VYVGART Hytrulo). Beyond its commercial indications, argenx is advancing efgartigimod in numerous Phase 2 and Phase 3 clinical trials across a broad range of severe autoimmune diseases in neurology, hematology, and rheumatology. The company's clinical pipeline also includes empasiprubart (ARGX-117), a novel C2 complement inhibitor in late-stage development for multifocal motor neuropathy (MMN) and other complement-mediated diseases, and ARGX-119, a MuSK agonist being evaluated for neuromuscular conditions. Geographically, argenx operates globally with major hubs in the Netherlands, Belgium, the United States, and Japan. The company generates the vast majority of its revenue from product sales of VYVGART, supplemented by collaboration revenues from strategic partnerships.
